GSK/Sanofi Covid vaccine delayed until end of next year
by Ian Sample Science editor from Science | The Guardian on (#5BH67)
Trials reveal vaccine failed to produce a strong immune response in older people
A coronavirus vaccine being developed by GlaxoSmithKline and its French partner, Sanofi, will be delayed until the end of next year after trials revealed it failed to produce a strong immune response in older people.
The drug companies hoped to have regulatory approval for the candidate vaccine in the first half of 2021, but interim results from a phase 1/2 trial showed an insufficient" response in the over-50s, the age group most vulnerable to severe Covid-19.
Continue reading...